← All trials
NCT04590586
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 24, 2020
- Primary completion
- Sep 20, 2021
- Completion date
- Sep 20, 2021
- First posted
- Oct 19, 2020
- Last posted
- Dec 23, 2020
- Enrollment
- 1400
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AmgenLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.